Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $15.34 USD
Change Today +0.08 / 0.52%
Volume 542.8K
BCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$15.15
Previous Close
$15.26
Day High
$15.57
Day Low
$14.87
52 Week High
07/20/15 - $16.83
52 Week Low
03/26/15 - $7.85
Market Cap
1.1B
Average Volume 10 Days
661.1K
EPS TTM
$-0.67
Shares Outstanding
72.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

50 Employees
Last Reported Date: 03/2/15
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $633.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $461.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $503.8K
Senior Vice President of Drug Discovery
Total Annual Compensation: $460.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2014.

biocryst pharmaceuticals inc (BCRX) Key Developments

BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited

BioCryst Pharmaceuticals, Inc. announced that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited. RAPIVAB is an intravenous (I.V.) treatment indicated in the U.S. for acute uncomplicated influenza in adults 18 years and older. It is also currently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world. RAPIVAB will be commercialized by CSL's subsidiary, bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets. Under the terms of the agreement, bioCSL obtains worldwide rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retains all rights to pursue pandemic stockpiling orders for RAPIVAB from the U.S. government, while bioCSL is responsible for government stockpiling outside the U.S. Under the terms of the agreement, BioCryst will receive an upfront payment of $33.7 million from bioCSL, and may receive up to $12.0 million in additional payments related to the successful achievement of certain regulatory milestones. BioCryst will receive tiered royalties that are contingent upon certain net sales thresholds in the U.S. and the rest of the world, as well as a percentage of proceeds from government stockpiling purchases outside the U.S. In addition, bioCSL will purchase existing and in-process inventory of RAPIVAB for treatment of influenza patients in upcoming flu seasons.

BioCryst Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:30 AM

BioCryst Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

BioCryst Pharmaceuticals, Inc. Announces Initiation of A Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. Discovered by BioCryst, BCX7353 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). BioCryst has successfully completed nonclinical safety studies, as well as in vitro studies in which BCX7353 exhibited potent and selective inhibition of plasma kallikrein. The pharmacokinetic profile of BCX7353 in preclinical studies indicates its potential for once daily dosing.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $15.34 USD +0.08

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,525 JPY +5.50
Dyax Corp $24.03 USD -0.23
GlaxoSmithKline PLC 1,389 GBp +14.50
Pharming Group NV €0.35 EUR +0.008
Shire PLC 5,590 GBp -110.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 65.0x
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.